Placebo News and Research

RSS

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.

2 Oct 2013

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

2 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

Overactive bladder treatments: an interview with Professor Chris Chapple, Consultant Urological Surgeon at the Royal Hallamshire Hospital and Sheffield Teaching Hospitals NHS Foundation Trust

Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Researchers discover how aspirin improves survival in patients diagnosed with colon cancer

Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer, the 2013 European Cancer Congress (ECC2013) heard today.

1 Oct 2013

FDA approves Brintellix drug to treat depressive disorder in adults

The U.S. Food and Drug Administration today approved Brintellix (vortioxetine) to treat adults with major depressive disorder.

1 Oct 2013

Researchers discover how aspirin improves survival in patients with colon cancer

Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer, the 2013 European Cancer Congress heard today (Monday).

30 Sep 2013

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress.

30 Sep 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Oxytocin helps humans accept others, study finds

Oxytocin - often referred to as the 'love hormone' because of its ability to promote mother-infant attachment and romantic bonding in adults - could also make us more accepting of other people, as found in new research, "Oxytocin Sharpens Self-other Perceptual Boundary," by Neuropsychoanalysis Foundation research grantee Valentina Colonnello Ph.D. published online today in Psychoneuroendocrinology.

30 Sep 2013

Doing yoga during menopause linked to less insomnia

Taking a 12-week yoga class and practicing at home was linked to less insomnia-but not to fewer or less bothersome hot flashes or night sweats. The link between yoga and better sleep was the only statistically significant finding in this MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) Network randomized controlled trial.

29 Sep 2013

Dextrose gel could treat neonatal hypoglycemia

A cheap and easy-to-administer dextrose gel should be used to treat low blood sugars in newborns (neonatal hypoglycaemia), a common problem that affects up to 15% of otherwise healthy babies, and a preventable cause of brain damage, according to new research published in The Lancet.

27 Sep 2013

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes.

27 Sep 2013

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

The Center of Reproductive Medicine today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos.

26 Sep 2013

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam.

26 Sep 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

25 Sep 2013

Placebo News and Research

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

Overactive bladder treatments: an interview with Professor Chris Chapple, Consultant Urological Surgeon at the Royal Hallamshire Hospital and Sheffield Teaching Hospitals NHS Foundation Trust

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Researchers discover how aspirin improves survival in patients diagnosed with colon cancer

FDA approves Brintellix drug to treat depressive disorder in adults

Researchers discover how aspirin improves survival in patients with colon cancer

Women with recurrent ovarian cancer survive longer after treatment with cediranib

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Discoveries pave way for use of new therapies for advanced thyroid cancer

Oxytocin helps humans accept others, study finds

Doing yoga during menopause linked to less insomnia

Dextrose gel could treat neonatal hypoglycemia

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News